Nicholas J. Short MDAssistant Professor, Department of Leukemia,The University of Texas MD Anderson Cancer Center, Houston, Texas
Dr. Nicholas Short is an Assistant Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas. He attended Baylor College of Medicine for medical school, and then completed internal medicine residency at Brigham and Women’s Hospital, followed by hematology/oncology fellowship at The University of Texas MD Anderson Cancer Center.
Dr. Short is a clinical and translational investigator in adult leukemias, with a particular emphasis on measurable residual disease and the development of phase I and II clinical trials of novel agents and combinations for patients with acute leukemias. Dr. Short has authored over 50 peer-reviewed manuscripts and numerous abstracts that have been presented at national and international conferences, including the American Society of Hematology and the American Society of Clinical Oncology. For his accomplishments in the field of leukemia research he has received a number of awards, including the Celgene Future Leaders in Hematology Award, American Society of Clinical Oncology Young Investigator Award, Leukemia SPORE Career Enhancement Award, and Paul Calabresi Career Development Award.
DisclosuresDr. Short is a consultant for Takeda Oncology.
Recent Contributions to PracticeUpdate:
- Clonal Hematopoiesis in the Elderly
- Molecular Profiling Predicts Outcomes With Hypomethylating Agents in Myelodysplastic Syndromes
- Myelodysplastic Syndrome and Acute Myeloid Leukemia in Patients Treated With PARP Inhibitors
- Circulating Cell-Free DNA for Molecular Characterization of Ph-Negative Myeloproliferative Neoplasms
- A Four-Gene Leukemic Stem Cell Score Predicts the Prognosis of Patients With MDS
- Lenalidomide as Second-Line Therapy After Failure of Hypomethylating Agents in MDS
- Deferasirox in the Management of Iron-Overload in Patients With Myelofibrosis
- Treatment of MDS After Hypomethylating Agent Failure
- ASXL1 as a Molecular Predictor for Pancytopenia and Survival in Idiopathic Cytopenia of Undetermined Significance